RedHill Biopharma (RDHL) Current Assets (2022 - 2024)
RedHill Biopharma (RDHL) has disclosed Current Assets for 3 consecutive years, with $11.9 million as the latest value for Q4 2024.
- Quarterly Current Assets fell 26.2% to $11.9 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $11.9 million through Dec 2024, down 26.2% year-over-year, with the annual reading at $11.9 million for FY2024, 26.2% down from the prior year.
- Current Assets for Q4 2024 was $11.9 million at RedHill Biopharma, down from $16.1 million in the prior quarter.
- The five-year high for Current Assets was $85.9 million in Q4 2022, with the low at $11.9 million in Q4 2024.
- Average Current Assets over 3 years is $38.0 million, with a median of $16.1 million recorded in 2023.
- The sharpest move saw Current Assets plummeted 81.21% in 2023, then decreased 26.2% in 2024.
- Over 3 years, Current Assets stood at $85.9 million in 2022, then tumbled by 81.21% to $16.1 million in 2023, then dropped by 26.2% to $11.9 million in 2024.
- According to Business Quant data, Current Assets over the past three periods came in at $11.9 million, $16.1 million, and $85.9 million for Q4 2024, Q4 2023, and Q4 2022 respectively.